A Phase 1/2, Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
Who is this study for? Patients with Multiple Myeloma
What treatments are being studied? CC-92480+Dexamethasone
Status: Active_not_recruiting
Location: See all (46) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY
The purpose of this study is to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
⁃ • Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2
⁃ For participants in Cohorts A, B, C, D, E, F, H, I, J, and K the following inclusions will also apply:
• Documented diagnosis of multiple myeloma (MM) and measurable disease
• Documented disease progression during or after their last antimyeloma regimen
• Achieved a response (minimal response \[MR\] or better) to at least 1 prior treatment regimen
Locations
United States
Colorado
Local Institution - 119
Denver
Florida
Local Institution - 104
Tampa
Georgia
Local Institution - 108
Atlanta
Illinois
Local Institution - 107
Chicago
Local Institution - 112
Chicago
Massachusetts
Local Institution - 101
Boston
Local Institution - 117
Boston
Local Institution - 118
Boston
Michigan
Local Institution - 113
Detroit
Minnesota
Local Institution - 106
Rochester
North Carolina
Local Institution - 110
Winston-salem
New Jersey
Hackensack University Medical Center
Hackensack
Ohio
Local Institution - 115
Columbus
Tennessee
Local Institution - 114
Nashville
Texas
Local Institution - 116
Houston
Washington
Swedish Cancer Institute
Seattle
Other Locations
Canada
Local Institution - 201
Calgary
Local Institution - 205
Edmonton
Local Institution - 204
Halifax
Local Institution - 202
Montreal
Local Institution - 203
Toronto
Denmark
Local Institution - 902
Odense
Local Institution - 903
Vejle
France
Local Institution - 703
Lille
Local Institution - 705
Marseille
Local Institution - 704
Nantes
Local Institution - 701
Toulouse
Local Institution - 702
Tours
Germany
Local Institution - 604
Freiburg Im Breisgau
Local Institution - 605
Hamburg
Local Institution - 601
Heidelberg
Local Institution - 602
München
Local Institution - 603
Würzburg
Greece
Local Institution - 301
Athens
Italy
Local Institution - 404
Brescia
Local Institution - 401
Milan
Local Institution - 403
Reggio Emilia
Local Institution - 402
Torino
Spain
Local Institution - 504
Badalona
Local Institution - 501
Madrid
Local Institution - 508
Madrid
Local Institution - 506
Málaga
Local Institution - 505
Pamplona
Local Institution - 502
Salamanca
Local Institution - 503
Santander
Local Institution - 507
Valencia
Time Frame
Start Date: 2019-09-30
Completion Date: 2026-11-30
Participants
Target number of participants: 424
Treatments
Experimental: Cohort A: CC-92480 with bortezomib and dexamethasone
Experimental: Cohort C: CC-92480 with carfilzomib and dexamethasone
Experimental: Cohort H: CC-92480 with elotuzumab and dexamethasone
Experimental: Cohort I: CC-92480 with isatuximab and dexamethasone
Experimental: Cohort D: CC-92480 with bortezomib and dexamethasone
Experimental: Cohort F: CC-92480 with carfilzomib and dexamethasone
Experimental: Cohort J: CC-92480 with elotuzumab and dexamethasone
Experimental: Cohort K: CC-92480 with isatuximab and dexamethasone
Experimental: Cohort G: CC-92480 with bortezomib and dexamethasone
Experimental: Subcohort B1: CC-92480 with daratumumab and dexamethasone
Experimental: Subcohort B2: CC-92480 with daratumumab and dexamethasone
Experimental: Subcohort B3: CC-92480 with daratumumab and dexamethasone
Experimental: Subcohort E1: CC-92480 with daratumumab and dexamethasone
Experimental: Subcohort E2: CC-92480 with daratumumab and dexamethasone
Experimental: Subcohort E3: CC-92480 with daratumumab and dexamethasone
Related Therapeutic Areas
Sponsors
Leads: Celgene